UK research reveals poor performance of National Health Service:
This article was originally published in Clinica
A report by the UK Institute of Economic Affairs has criticised the country's National Health Service (NHS) as being one of the worst in the developed world with virtually the lowest cancer and heart disease survival rates in Europe. The problem, say the co-authors David Green and Laura Casper, is caused by the UK's low healthcare expenditure with the country spending only 6.9% of GDP on healthcare compared with Germany which spends 10.7% and France which spends 9.6%. This results in shortages in medical equipment, drugs and human resources throughout the NHS, says the report.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.